Past, Present and Future Oncology: Welcome to Volume 17

Figures & data

Table 1. Top three Future Oncology articles.

Rank	Title	Authors	Page views/downloads	Ref.
1.	Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study	Hochair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JCH, Gucalp R, Halmos B, Märten A & Cufer T	15,594	[7]
2.	Suspected cancer symptoms and blood test results in primary care before a diagnosis of lung cancer: a case–control study	McDonald L, Carroll R, Harish A, Tanna N, Mehmud F, Alikhan R & Ramagopalan SV	8390	[8]
3.	Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3	Yoshioka H, Kato T, Okamoto I, Tanaka H, Hida T, Seto T, Kiura K, Tian Y, Azuma H & Yamamoto N	7566	[9]

NSCLC: Non-small-cell lung carcinoma.

Figure 1. Papers published in Future Oncology during 2020, ordered by country.

Figure 2. Readership in Future Oncology during 2020.

Hochmair MJ , MorabitoA, HaoDet al. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncol.16(34), 2799–2808 (2020).

 PubMed Web of Science ®Google Scholar

McDonald L , CarrollR, HarishAet al. Suspected cancer symptoms and blood test results in primary care before a diagnosis of lung cancer: a case–control study. Future Oncol.15(33), 3755–3762 (2019).

 PubMed Web of Science ®Google Scholar

Yoshioka H , KatoT, OkamotoIet al. Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Future Oncol.16(4), 49–60 (2020).

 PubMed Web of Science ®Google Scholar